Mary Szela resigns as CEO of Novelion; China is proving to be a rewarding market for AstraZeneca
→ After reorganizing Aegerion and leading the company through the merger with QLT that turned it into Novelion, CEO Mary Szela is leaving her position for personal reasons. Her resignation is effective immediately, and while the rare disease biotech $NVLN searches for a new CEO, a team of three execs will fill the office. Later this month, Murray Stewart will join as EVP and head of R&D, as the company prepares to launch Juxtapid in Japan and anticipates an EMA approval for metreleptin (Myalept) early next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.